Correction: MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances - Report - MDSpire

Correction: MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances

  • By

  • Ye Chen

  • Huiyi Liu

  • Peipei Yuan

  • Yongqi Li

  • Changqiong Xu

  • Ran Li

  • Jibing Chen

  • Fasheng Wu

  • June 24, 2026

  • 0 min

Share

Clinical Report: Update on MicroRNA for Glioblastoma Diagnosis and Treatment

Background

Glioblastoma (GBM) is the most common and aggressive primary brain tumor, characterized by poor prognosis and high recurrence rates despite existing treatment options. Current guidelines emphasize established molecular markers, and miRNA testing is considered investigational.

Data Highlights

No numerical or trial data is provided in the source material.

Key Findings

  • GBM remains the most prevalent and fatal primary malignant brain neoplasm in adults.
  • Recent literature indicates that circulating miRNAs may serve as potential diagnostic biomarkers for glioma.
  • A systematic review/meta-analysis reported pooled sensitivity of 0.83 and specificity of 0.88 for blood miRNAs across glioma cohorts.
  • New data suggest strong discrimination of GBM from controls using paired miRNA ratios in pre-resection plasma.
  • Current guidelines do not incorporate miRNA assays into routine diagnostic workflows for GBM.

Clinical Implications

Current guidelines do not recommend the use of miRNA profiling in routine practice for glioblastoma diagnostics.

Conclusion

The role of microRNA in the diagnosis and treatment of glioblastoma is an area of ongoing research.

Related Resources & Content

  1. Chen Y, Liu H, Yuan P, et al., Frontiers in Immunology, 2026 -- MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances
  2. Frontiers in Immunology — Integrating multiomics to elucidate the role of chromatin remodeling in glioma and the antitumor mechanisms and therapeutic potential of targeting LMNA
  3. Frontiers in Oncology — Editorial: Innovative strategies in overcoming glioblastoma: advancements in treatment and research
  4. Journal of Neuro-Oncology — Implications for Diagnosis and Treatment of IDH Mutations in Gliomas Post-2021 WHO CNS Tumor Classification
  5. AOSNP‐ADAPTR resource level‐based recommendations on practical diagnostic strategies for WHO CNS5 adult‐type diffuse gliomas
  6. Diagnostic Potential of Circulating miRNAs in Glioma: A Systematic Review and Meta-Analysis
  7. Frontiers | MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances

Original Source(s)

Correction: MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances

  • by Ye Chen, Huiyi Liu, Peipei Yuan, Yongqi Li, Changqiong Xu, Ran Li, Jibing Chen, Fasheng Wu

  • June 24, 2026

Related Content

CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies

Adjuvant radiotherapy for WHO grade II meningiomas: the unanswered question

Endocrine-driven inflammatory–epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis